Assuntos
Anticoncepcionais Orais Combinados/farmacocinética , Citocromo P-450 CYP3A/metabolismo , Fígado/metabolismo , Taxa de Depuração Metabólica/efeitos dos fármacos , Administração Oral , Indutores do Citocromo P-450 CYP3A/farmacologia , Inibidores do Citocromo P-450 CYP3A/farmacologia , Feminino , HumanosAssuntos
Benzimidazóis/uso terapêutico , Aprovação de Drogas , Serotoninérgicos/uso terapêutico , Disfunções Sexuais Psicogênicas/tratamento farmacológico , United States Food and Drug Administration , Comitês Consultivos , Benzimidazóis/efeitos adversos , Interações Medicamentosas , Feminino , Humanos , Pré-Menopausa , Serotoninérgicos/efeitos adversos , Estados UnidosRESUMO
Quality by design is an essential part of the modern approach to pharmaceutical quality. There is much confusion among pharmaceutical scientists in generic drug industry about the appropriate element and terminology of quality by design. This paper discusses quality by design for generic drugs and presents a summary of the key terminology. The elements of quality by design are examined and a consistent nomenclature for quality by design, critical quality attribute, critical process parameter, critical material attribute, and control strategy is proposed. Agreement on these key concepts will allow discussion of the application of these concepts to abbreviated new drug applications to progress.
Assuntos
Desenho de Fármacos , Indústria Farmacêutica/normas , Medicamentos Genéricos/normas , Controle de Qualidade , Estados Unidos , United States Food and Drug AdministrationRESUMO
Over the past decade, concerns have been expressed increasingly regarding the difficulty for highly variable drugs and drug products (%CV greater than 30) to meet the standard bioequivalence (BE) criteria using a reasonable number of study subjects. The topic has been discussed on numerous occasions at national and international meetings. Despite the lack of a universally accepted solution for the issue, regulatory agencies generally agree that an adjustment of the traditional BE limits for these drugs or products may be warranted to alleviate the resource burden of studying relatively large numbers of subjects in bioequivalence trials. This report summarizes a careful examination of all the statistical methods available and extensive simulations for BE assessment of highly variable drugs/products. Herein, the authors present an approach of scaling an average BE criterion to the within-subject variability of the reference product in a crossover BE study, together with a point-estimate constraint imposed on the geometric mean ratio between the test and reference products. The use of a reference-scaling approach involves the determination of variability of the reference product, which requires replication of the reference treatment in each individual. A partial replicated-treatment design with this new data analysis methodology will thus provide a more efficient design for BE studies with highly variable drugs and drug products.